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Abstract 
 
Distillers’ dried grains with solubles (DDGS) is a low value agro-industrial by-product, rich 
in arabinoxylans (AX), which is produced by commercial distillery and bioethanol plants. In 
a first approach, we investigated the prebiotic potential of four fractions comprising 
arabinoxylan oligosaccharides (AXOS) and xylo-oligosaccharides (XOS) obtained by 
enzymatic hydrolysis of AX fractions derived from DDGS and wet solids (in-process sample 
of DDGS production process). Anaerobic batch cultures in controlled pH conditions were 
used to test the prebiotic activity of the samples. Results did not show significant differences 
between the enzymatic treatments used and all AXOS/XOS were extensively fermented after 
24 h. In addition, significant increases (P<0.05) in Bifidobacterium and total SCFAs were 
observed after 24 h of fermentation. Finally, DDGS-derived hydrolysates were separated on 
an anionic semi-preparative column to prepare AXOS/XOS fractions with degree of 
polymerisation (DP) greater than 3. Bifidogenic activity and an increase of SCFAs were 
again observed after 24 h of fermentation, although this time the selectivity was higher and 
the fermentation slower, suggesting that the fermentation of this substrate could take place (at 
least partially) in the distal part of the colon with highly desirable beneficial effects.  
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Introduction 
 
Gut microbiota plays an important role in the host physiology. Imbalances in the microbiome 
have been associated with diseases such as inflammatory bowel diseases (IBDs), irritable 
bowel syndrome (IBS), colorectal cancer or metabolic syndrome (Sobhani et al. 2011; Collins 
2014; Festi et al. 2014; Machiels et al. 2014). The composition of the gut microbiota is 
strongly influenced by different factors including age, host genetics, antibiotic use, 
immunological factors and diet (Biagi et al. 2010; Zhang et al. 2010; Perez-Cobas et al. 2013; 
Suzuki and Worobey 2014). Dietary habit is one of the main factors contributing to the 
diversity of the gut microbiota. In this regard, the consumption of probiotics, prebiotics or the 
combination of both (synbiotics) is a widely used dietary intervention aimed to beneficially 
modulate the composition of the intestinal microbiota for the treatment or prevention of 
gastrointestinal diseases (Wasilewski et al. 2015).  
Although both probiotics and prebiotics have high potential for health enhancement and 
disease prevention, prebiotics have an advantage over probiotics in the lack of viability issues 
during their commercial storage and gastrointestinal passage. Prebiotics are defined as “a 
substrate that is selectively utilized by host microorganisms conferring a health benefit” 
(Gibson et al. 2017). In this regard, the main targeted microorganisms for prebiotics are 
Bifidobacterium and Lactobacillus species (Gibson 2004). Beneficial physiological effects of 
prebiotics are associated mainly with the production of Short Chain Fatty Acids (SCFAs) 
(LeBlanc et al. 2017; Wong et al. 2006) and with the immunological activities resulting from 
microbiota modulation in the colon (Klaenhammer et al. 2012). Galactooligosaccharides 
(GOS) and inulin-type fructans are among the most common and extensively studied 
prebiotics with well demonstrated bifidogenic effects (Vulevic et al. 2015; Vandeputte et al. 
2017; Davis et al. 2011). In the last decade, there had been a growing interest in the 
development of novel prebiotics driven by the increased interest in management of human 
health through nutrition, especially by the modulation of gut microbiota (Biswal et al. 2017). 
All the studies carried out on established prebiotics have enabled the better understanding of 
mechanisms of action and properties, which have provided the basis for emerging prebiotics 
including a range of plant cell wall polysaccharides (Gullon et al. 2013). The only currently 
marketed oligosaccharides that are obtained from lignocellulosic biomass are xylo-
oligosaccharides (XOS) (Moniz et al. 2014) with Asian countries being the main producers as 
their market is still small in Europe and the US.  
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XOS are mainly obtained by autohydrolysis of xylans, which consist of a linear backbone of 
β-(1→4) linked xylose. The xylose units can be either unsubstituted or mono- or di- 
substituted with α-L-arabinofuranosyl (Araf) residues positioned on C-(O)-2 and/or C-(O)-3 
positions, forming arabinoxylans (AX) (Saulnier et al. 2007). In addition, xylose residues can 
be substituted with glucuronic acid or acetyl groups, while arabinose residues can be 
esterified with phenolic acids, notably ferulic acid. AX constitutes the major polysaccharide 
in cereal grain cell walls and its hydrolysis with β-endoxylanase yields a mixture of 
arabinoxylan oligosaccharides (AXOS) and XOS (Saulnier et al. 2007). Several in vivo and 
in vitro studies (Francois et al. 2012; Finegold et al. 2014; Gullon et al. 2014) have 
determined the prebiotic potential of AXOS/XOS fractions showing the enrichment of 
Bifidobacterium species which have been well documented to promote a number of health 
benefits for the host (Picard et al. 2005; Russell et al. 2011). Furthermore, XOS/AXOS 
possess some advantages over other prebiotics already established in the market. For 
example, XOS exhibit greater resistance to pH and high temperatures than FOS (Wang et al. 
2009) and have been shown to be effective with a lower daily intake (Singh et al. 2015). 
Distillers’ dried grain with solubles (DDGS) is the main by-product of bioethanol and 
distillery plants and is produced in large amounts annually worldwide. Currently it is 
principally used as nutrient supplement in livestock feed due to its high content of protein, 
water soluble vitamins and minerals (Klopfenstein et al. 2008; Schingoethe et al. 2009). 
Additionally, DDGS is rich in AX and therefore could be a valuable feedstock for AXOS 
production, increasing the economic value of the by-product as well as contributing to the 
sustainable development of bioethanol and distillery plants. 
In a previous study, we (Chatzifragkou et al. 2016) investigated the extractability of protein 
from DDGS and in-process samples, such as wet solids (WS), in order to establish potential 
non-animal feed applications. In the present study, the solid residue of DDGS and WS 
samples obtained after protein extraction were investigated as a suitable substrate for 
enzymatic hydrolysis, in order to produce AXOS/XOS. The generated AXOS/XOS fractions 
were analysed for prebiotic potential, using pH–controlled anaerobic batch fermentation 
vessels inoculated with human faecal microbiota to simulate the distal human colonic region. 
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Materials and Methods 
 
Materials 
 
DDGS and wet solids (WS) were provided by a commercial distillery plant in UK. The 
samples were lyophilized in a VirTis Bench Top (USA) freeze-drier for 48 h at -55 °C and 
stored at -20°C.  
Enzymatic production and purification of AXOS/XOS 
 
Deproteinised DDGS and WS (Chatzifragkou et al. 2016) were used for the enzymatic 
production of oligosaccharides. A commercial, food-grade GH11 endo-xylanase (17 U/mL, 
Depol 761P, Biocatalysts, Cardiff, Wales, UK) was used solely or in combination with a 
beta-glucanase with feruloyl esterase side activity, here after referred to as FAE (4 U/mL, 
Depol 740L, Biocatalysts Cardiff, Wales, UK) for the hydrolysis of deproteinised DDGS and 
WS. These were used as substrates for enzymatic hydrolysis in concentrations of 10% (w/v), 
incubated at 55 °C for 24 h. Upon completion of the enzymatic reaction, supernatants were 
collected by centrifugation and analysed for their carbohydrate content. Total carbohydrate 
content was determined according to (Dubois et al. 1956). The oligosaccharide profile of the 
hydrolysates was monitored by High-Performance Anion-Exchange Chromatography with 
Pulsed Amperometric Detection (HPAEC-PAD, Thermo Fisher), on Dionex Carbopac 
PA1column (10µm, 4.0 x 250 mm) (Thermo Scientific,  Loughborough, UK). A gradient 
analysis was carried out using (A) water, (B) 1M sodium acetate and (C) 0.5 M NaOH 
eluents. Running conditions were 0 min (A: 80%, C:20%), 30 min (A:63%, B:17%, C:20%), 
35 min (A: 60%, B&C:20%), 40 min (A: 57.5%, B:22.5%, C:20%), 41 min (B:80%, C:20%) 
and 47 min up to 65 min (A:80%, C:20%), at a flowrate of 1 mL/min. Linear 
xylooligosaccharides up to DP6 were identified using commercially available standards 
(Megazyme, Bray, Ireland). Substituted or higher DP oligosaccharides were identified 
according to Kosik et al. (2017), using wheat flour as substrate. Furthermore, enzymatic 
hydrolysates of DDGS and WS were fractionated by gel filtration, in order to generate 
fractions with oligosaccharides of DP ≥3. Oligosaccharides were separated on Biogel P2 
(Biorad, Hercules, Ca, USA)) column eluted at 3 mL/min with deionised water (Tzortzis et 
al. 2005). A description of all tested DDGS and WS samples is given in Table 1.  
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Faecal sample preparation 
 
Batch culture fermentations were carried out using fresh faecal samples provided by three 
healthy volunteers (one male, two females; age 24-33 years, omnivores). Donors were free of 
known metabolic and gastrointestinal diseases and had not received any antibiotic or 
probiotic treatment for at least 6 months prior to the experiment. Faecal samples were 
collected in sterile plastic containers which were stored in anaerobic jars containing 
AnaeroGen sachets (Oxoid, Basingstoke, UK). Stool samples were used within 2 hours of 
collection. Faecal samples were diluted in sterile phosphate-buffered saline (PBS) and 
homogenised in filters bags using a stomacher (Stomacher 400, Seward, Worthing, UK) for 4 
min to remove large particles. Resulting faecal slurries were used to inoculate the batch-
culture systems. 
In vitro batch cultures 
 
100-mL sterile batch fermentation vessels (50 mL working volume) were aseptically filled 
with 45 mL of sterile basal nutrient medium and sparged with O2- free N2 (15 mL/min) 
overnight to establish anaerobic conditions. The basal medium (per litre) consisted of: 2 g 
peptone water, 2 g yeast extract, 0.1 g NaCl, 0.04 g K2HPO4, 0.04 g KH2PO4, 0.01 g 
MgSO4.7H2O, 0.01 g CaCl.6H2O, 2 g NaHCO3, 2 mL Tween 80, 0.05 g hemin, 0.01 mL 
vitamin K1, 0.5 g L-cysteine-HCl, 0.5 g bile salt and 4 mL resazurin solution (0.25 g/L). The 
positive control FOS (Orafti® P95, Beneo, Upton upon Severn, UK) and dried substrates of 
AXOS/XOS hydrolysates were added (1% w/v) to the respective fermentation vessels just 
before the addition of the faecal slurry. Vessels were incubated at 37° C using a circulating 
water bath and the pH was controlled between 6.7 and 6.9 using an automated pH controller 
(Fermac 260, Electrolab, Tewkesbury, UK). Each vessel was inoculated with 5 ml of fresh 
faecal slurry (1:10, w/w). Batch cultures were conducted for 24 h, and samples of 3.5 mL 
were collected from each vessel at 0, 4, 8 and 24 h for counting of bacterial populations, 
SCFA analyses and for determining carbohydrate assimilation profiles during fermentation. 
In a second stage of the study, in order to test the prebiotic activity of AXOS with DP ≥ 3, 
10-mL minibatch vessels were used. In this case, samples were collected at time points of 0, 
8 h and 24 h, while FOS and a commercial XOS (Longlive Bio-Technology, Shandong, 
China) product were used as positive controls. The fermentations of purified AXOS with DP 
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≥ 3 were carried out in duplicate and all the other fermentations in triplicate with different 
donors. 
Lactate and short chain fatty acid analysis 
 
Samples (1 mL) taken at each fermentation time point were centrifuged at 13,000 xg for 10 
min. Supernatants were filtered through a 0.22 µm Millipore syringe filter. HPLC was 
performed using an Agilent 1100 series HPLC (Hewlett–Packard, Agilent, Bracknell, UK) 
equipped with a Refractive Index (RI) Detector. The ion-exclusion REZEX-ROA Organic 
acid column (Phenomenex Inc., Macclesfield, UK) was maintained at a constant temperature 
of 85 ºC. The eluent was sulphuric acid in HPLC water (0.0025 mmol/ L), with a flow rate of 
0.5 mL/ min. Calibration curves for lactate, acetate, formate, propionate and butyrate were 
accomplished for SCFA quantification. The mean metabolite concentrations were expressed 
as mM. 
 
Flow Cytometry-Fluorescence in situ hybridization 
 
Collected samples (750 µL) were centrifuged at 10,000 xg for 5 min at room temperature. 
Pellets were fixed for further fluorescence in situ hybridization and kept at -20 °C. Briefly, 
after centrifugation pellets were re-suspended in 375 µL of 1X PBS and 1,125.5 µL of cold 4 
% (w/v) paraformaldehyde. Suspension was mixed and stored at 4 ºC for 4–6 h. After 
incubation, samples were washed twice with 1 mL of 1X PBS. Finally, samples were 
centrifuged at 10,000 xg for 5 min, the supernatant was discarded and the pellet was re-
suspended in 300 µL of 1X PBS and 300 µL of ethanol. Samples were vortexed and stored at 
–20 ºC for further analysis. For Flow-FISH cytometry, the 16S ribosomal RNA molecule 
labelled with the fluorescent was used for the enumeration of bacterial groups (Table 2). 
75 µL aliquots of the fixed samples were collected from the fixed cell solutions stored at -20 
ºC. The fixed cells were washed twice with PBS and pre-treated for 10 min with lysozyme at 
1mg/mL. Cells were re-suspended in 1 mL of hybridization buffer (HB). All hybridizations 
were performed in the dark at 35 °C overnight in the hybridization solution containing the 
appropriate labelled probe (Table 2). Cells were centrifuged at 10,000 xg for 3 min, re-
suspended in pre-warmed washing buffer and incubated at 37 °C for 20 min to remove non-
specific binding of the probe. Finally, cells were centrifuged at 10,000 xg for 3 min and re-
suspended in PBS for flow cytometry analysis.  
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Statistical studies 
 
Statistical analyses were performed using SPSS for Windows, version 21. Univariate analysis 
of variance and Tukey’s posthoc test was used to determine significant changes in the 
microbiota populations and SCFA concentrations at inoculation and subsequent sampling 
points and to compare differences in the effects of the different substrates at the same time 
point. Differences were considered to be significant when P < 0.05. 
 
Results 
 
Prebiotic potential of produced AXOS/XOS hydrolysates 
 
Substrates consumption 
 
Hydrolysates treated only with endo-xylanase showed initially lower amounts of xylose and 
xylobiose (6.06% ± 4.06 and 2.08 ± 1.41) than samples treated with the combination of the 
two enzymes (Xylanase and FAE) (15.43 ± 4.74 and 12.16 ± 8.03). Supplemental Table S1 
shows the AXOS/XOS consumption over the course of fermentation by faecal microbiota. 
The three donors showed slight variations in magnitude and trends that coincided with higher 
standard deviations. All substrates were totally consumed between 8 and 24 h of 
fermentation. Oligosaccharides obtained from DDGS were almost totally depleted after 8 h of 
fermentation in donors 1 and 2 while AXOS/XOS obtained from WS were consumed slower 
(between 8 and 24 h of fermentation) (Fig. 1). In donor 3 (data not shown), all substrates 
(DDGS and WS) were almost totally consumed after 8 h of fermentation. The different 
assimilation profiles observed among donors and time points agreed with the growth kinetic 
of total bacteria. In this regard, the maximum bacterial population was obtained at 8 h in the 
case of DDGS substrates and at 24 h with WS substrates. For donor 3 the maximum bacterial 
population occurred at 8 h for both DDGS- and WS- derived oligosaccharides.  
 
Enumeration of specific bacterial populations  
 
Bacterial group counts during the batch cultures fermentations of the different AXOS 
substrates are shown in Fig. 2 and Supplemental Table S2.  
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Overall, the most notable impact of AXOS/XOS fermentation on the composition of the 
faecal microbiota was the population growth of Bifidobacterium. AXOS/XOS utilization by 
faecal microbiota resulted in statistically significant increases (P < 0.05) in Bifidobacterium 
counts after 24 h of fermentation for all AXOS/XOS hydrolysates tested (Fig. 2 and 
Supplemental Table S2). Specifically increases between 1.3-1.7 log were observed at the end 
of the fermentation (Fig. 2). In addition, DDGS hydrolysates treated with xylanase (DDGS-
Xyl) and wet solid hydrolysates generated with xylanase and feruloyl esterase (WS-
Xyl+FAE) also increased significantly Bifidobacterium populations after 8 h of fermentation. 
Populations of Bacteroides-Prevotella (BAC) and propionate producing bacteria (PROP) 
were increased by more than 10-fold between 8 and 24 h of fermentation with all 
AXOS/XOS substrates except for DDGS-Xyl+FAE; although significant differences were 
only observed when WS-Xyl+FAE was used as substrate. The wet solids hydrolysates also 
increased the growth of bacteria detected by Lab158 (Lactobacillus-Enterococcus group) in 
more than 10-fold over 24 h fermentation, but the differences were not significant when 
compared to time 0 or the negative control. A significant reduction in the population of 
Faecalibacterium prausnitzii was detected after 8 h and 24 h when the FOS (positive control) 
was used as substrate. No significant changes were detected in any other enumerated bacterial 
populations (Supplemental Table S2). 
 
Organic acid production in faecal batch cultures  
 
The production of SCFAs (acetate, formate, propionate and butyrate) and lactate determined 
during the fermentation in batch cultures. All substrates tested, except DDGS-Xyl+FAE, 
significantly increased the total SCFA concentrations (P < 0.05) after 8 h and 24 h of 
fermentation (Fig. 3). Acetate was the main SCFA detected during the fermentation of all 
tested substrates and its production accounted for approximately 65% of total SCFAs. 
Significant increases in acetate (P < 0.05) were also observed at 8 h and 24 h of fermentation 
with the AXOS substrates, except for DDGS-Xyl+FAE (P = 0.06). A significant increase in 
lactate was also observed at 8 h of fermentation with all substrates except in WS-Xyl 
(Supplemental Table S3). During the period 8-24 h, lactate was significantly depleted which 
is consistent with the fact that this product can be utilised by other groups of bacteria to 
produce acetate, propionate or butyrate (cross-feeding).  
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Substantial increases in the concentration of propionate, the second most abundant SCFA 
after acetate, and moderate increases in butyrate were also observed after 24 h (Supplemental 
Table S3) although no significant differences were observed between the time points because 
of the variation in responses found between donors. Similarly, no significant differences were 
found in formic production after 24 h of fermentation. 
 
 
Prebiotic potential of purified AXOS/XOS 
 
Fig. 4 shows the carbohydrate profiles from commercial XOS and purified hydrolysates of 
AXOS/XOS DP ≥ 3 obtained from DDGS during fermentation. Commercial XOS were more 
quickly fermented than AXOS/XOS DP ≥ 3 where some oligosaccharides were still present 
at 24 h. Overall, both XOS and AXOS DP ≥ 3 were broken down without increases in xylose. 
Counts of all bacterial group during the mini-batch cultures are shown in Supplemental Table 
S4. The most noticeable change in the microbiota composition in the presence of 
oligosaccharides was a significant increase of Bifidobacterium numbers (Fig. 5). While 
commercial XOS and FOS resulted in significant increases in Bifidobacterium at 8 h and 24 h 
of fermentation, the bifidogenic effect of AXOS fractions DP ³ 3 was more gradual (Fig. 5). 
No significant changes were detected in any of the other bacterial populations enumerated. 
Acetate was the main SCFA detected and represented 60% - 65% of total SCFAs. Across all 
substrates, formate and lactate were transient metabolites reaching maxima at 8 h (Table 3). 
Different profiles of production of butyrate and propionate were observed between 
commercial FOS and XOS and AXOS/XOS DP ³ 3. FOS and XOS resulted in increases in 
butyrate after 24 h which accounted for approximately 12% of total SCFAs. However, the 
fermentation of AXOS/XOS DP ³ 3 resulted in significantly increased production of 
propionate and reduction of butyrate levels compared to the fermentation of FOS and XOS 
after 24 h.  
Discussion 
 
The present study aimed to demonstrate the prebiotic potential of AXOS/XOS derived from 
wheat DDGS and in-process samples on human faecal microbiota.  
The main characteristic of a prebiotic compound is to induce a selective stimulation of 
beneficial bacteria in the colon microbiota (Gibson et al. 2017). In this regard, the 
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Bifidobacterium genus is the most frequent target for prebiotics. Numerous species of 
Bifidobacterium have been studied and demonstrated as probiotic agents. A range of health-
promoting activities have been described for bifidobacteria in recent years including 
reduction in serum cholesterol, prevention of colo-rectal cancer, prevention of infectious 
diarrhoea, modulation of mucosal barrier function and production of amino acids and 
vitamins (Xiao et al. 2003; D'Aimmo et al. 2012; Zanotti et al. 2015). This study showed that 
AXOS hydrolysates promoted bifidogenic activity during the fermentation of the substrates. 
Selectivity of AXOS/XOS substrates for bifidobacteria was observed in the period between 0 
and 8 h, where most of the oligosaccharides were consumed. Moderate increases in other 
groups of bacteria (Bacteroides-Prevotella and Clostridia cluster IX) were detected 
simultaneously with the significant bifidogenic effect after 8 h and it is notable that several 
members of these groups of bacteria have been reported to be able to degrade xylan (Wang et 
al. 2016; Zhang et al. 2016). However, Bifidobacterium was able to compete more 
successfully for XOS/AXOS during the first 8 h, demonstrating faster growth than 
Bacteroides/Prevotella. Additionally, the proliferation of the Clostridium cluster IX after 8 h 
could also result from cross feeding using the lactate and acetate generated by 
Bifidobacterium. A closer examination of the samples donor by donor revealed that in 
general, the bifidogenic effect was smaller in donor 3. The ability of Bifidobacterium to grow 
on XOS is reported to be depended on the strain (Riviere et al. 2014) and a different 
composition of Bifidobacterium in donor 3 could be the responsible factor of this inter-
individual variation.  
SCFAs produced during oligosaccharides fermentation by commensal bacteria in the colon 
are known to contribute to multiple benefits to the host (Koh et al. 2016). In this study, 
AXOS increased the production of total SCFAs with the greatest contribution to this increase 
being the production of acetate. The significant increases in acetate and lactate at 8 h could 
relate to the significant growth of the acetate and lactate producing Bifidobacterium group. 
Although not statistically significant, the increases in butyrate during AXOS fermentation 
could be related to the increases abundance of the Clostridium IX group which includes 
several butyrate producers. This would explain why no increases in butyrate were observed 
with the positive control which did not induce the growth of Clostridium IX groups and 
significantly reduced the main butyrate producer F. prausnitzii after 24 h. Propionate was the 
second most abundant SCFA produced; its production has been reported to be related with 
the presence of side chains in xylooligosaccharides (XOS) such as in AXOS (Broekaert et al. 
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2011; Gullón et al. 2014) and with increases in the Bacteroides-Prevotella group (Hughes et 
al. 2008) and Clostridium Cluster IX. 
The enzymatic hydrolysis of DDGS and wet solids by endo-xylanases or by the combination 
of endo-xylanases and FAE enzymes did not result in marked differences in terms of 
prebiotic activity of the hydrolysates. The mixture of these two enzymes was expected to 
exert a synergistic action on the hemicellulose polymer of DDGS and WS residues, that 
would in turn improve the solubilisation of AX as well as release ferulic acid as a high value 
co-product. However, the combination of enzymes also resulted in higher amounts of 
arabinose, xylose (X1) and xylobiose (X2) compared to the hydrolysates generated only by 
endo-xylanases. The presence of large amounts of monosaccharides and disaccharides in 
prebiotic products is frequently undesirable since these can be metabolized before reaching 
the large intestine and hence reducing their ability to stimulate the growth and/or activity of 
health-promoting bacteria. Therefore, although no statistical differences were observed in our 
study between the in vitro prebiotic activity of the enzyme treatments, a further study was 
carried out to purify oligosaccharides of DP ≥ 3 that are expected to have higher persistence 
in the intestine. The persistence of prebiotics in the intestine is one of the main aims for 
prebiotic development. Some chronic diseases, such as ulcerative colitis and colon cancer, 
frequently start in the distal colon where a more proteolytic environment exists before 
progressing towards the proximal region, which is characterised by higher saccharolytic 
activity (Macfarlane et al. 1992). Consequently, prebiotics that reach the distal region of the 
colon could display an advantage in the prevention of some intestinal diseases. A strategy to 
achieve this effect is to increase the molecular weight of the prebiotic oligosaccharides. In 
this regard, AXOS/XOS fractions with DP ≥ 3 obtained from DDGS showed slower 
fermentation compared to the commercial XOS and the unfractionated AXOS/XOS 
hydrolysates that were totally depleted after 24 h of fermentation. Commercial XOS are 
composed of xylobiose (35%) and 60% total fibre (non-digestible oligomers; n=3-6) with 
xylose backbones. The removal of xylobiose and the presence of arabinoxylans in our 
DDGS-derived hydrolysate appeared to positively influence the utilisation of these 
carbohydrates by faecal Bifidobacterium. The slow production of SCFAs and the slower 
growth of Bifidobacterium reflect slower fermentation that could be an indicator of a higher 
prebiotic selectivity. The multiple side branches present in AXOS compared to commercial 
FOS or XOS could require more and different enzymes for their hydrolysis, restricting the 
fermentation of these substrates to less bacterial species. The presence of small amounts of 
carbohydrates not exhaustively fermented at 24 h with AXOS/XOS DP ≥ 3, suggests the 
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potential increase in the bifidobacteria population after 24 h. On the other hand, the higher 
production of propionate during fermentation of AXOS DP ≥ 3 has been related to the 
presence of side chains in xylooligosaccharides (XOS) such as those in AXOS (Broekaert et 
al. 2011; Gullon et al. 2014). This increase of propionate in our study agrees with increases in 
the populations of propionate producing bacteria such as Clostridium Cluster IX and 
Bacteroides.  
In summary, DDGS and wet solids obtained from distillery plants were successfully used as 
substrates for the enzymatic production of AXOS/XOS with potential prebiotic activity. The 
in vitro fermentation of AXOS hydrolysates showed high stimulatory effect on 
Bifidobacterium. Removal of monosaccharides and disaccharides from these hydrolysates 
resulted in slower growth of Bifidobacterium and higher propionate concentration than 
commercial prebiotics such as FOS and XOS. This slower fermentation could be 
advantageous allowing at least a proportion of the AXOS/XOS to reach the distal part of the 
colon with beneficial effects on disorders which occur in this region. AXOS/XOS from 
DDGS could be a promising option to other established prebiotics such as FOS due to the low 
cost of the material source and easy low-cost extraction methods. Further studies using gut 
models and human intervention will be required to confirm the prebiotic efficacy of 
AXOS/XOS obtained from DDGS. 
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Fig. 1: AXOS/XOS hydrolysates assimilation in pH-controlled batch cultures for donor 1 at 
time 0 h, 4 h and 8 h after fermentation. X1, X2, X3, X4, X5, X6 are xylose, xylobiose and 
xylotriose, xylotetraose, xylopentaose and xylohexose respectively. XA3XX is 33-α-L-
arabinofuranosyl-xylotetraose. At 24 h there was no detectable sugar remaining in all the 
culture samples. 
 
Fig. 2: Some of the bacterial populations analysed by Flow-FISH in batch cultures containing 
different substrates: Error bars indicate SD (n = 3).  Significant differences between 
substrates at the same time point are indicated with letters (P < 0.05).  
Asterisks indicate significantly different compared to 0 h within the same substrate 
(P < 0.05). 2-way ANOVA with Tukey’s post hoc tests were used for the statistical analysis. 
 
Fig. 3: Total SCFAs and acetic concentrations (mM) obtained in pH controlled batch cultures 
at 0, 4, 8 and 24 h of fermentation of different substrates. Error bars indicate SD 
(n = 3). Significant differences between substrates at the same time point are indicated with 
letters. Asterisks indicate significantly different compared to 0 h within the same substrate * 
(P < 0.05), ** (P < 0.01) and *** (P < 0.001). 2-way ANOVA with Tukey’s post hoc tests 
were used for the statistical analysis. 
 
Fig. 4: AXOS/XOS fractions (DP ³ 3) assimilation in pH-controlled batch cultures 
immediately after inoculation (Time 0 h) and after 8 h and 24 h of fermentation. X3, X4, X5 
and X6 are xylotriose, xylotetraose, xylopentaose and xylohexose respectively. XA3XX is 33-
α-L-arabinofuranosyl-xylotetraose. 
 
Fig. 5: Bifidobacterium abundance along the fermentation under different substrates: NC 
(Negative control), FOS (positive control), commercial XOS (Longlive Bio-Technology, 
Shandong, China) and AXOS fractions DP ³3 obtained from DDGS. Error bars indicate SD 
(n = 3). Significant differences between substrates at the same time point are indicated with 
letters. 2-way ANOVA with Tukey’s post hoc tests were used for the statistical analysis. 
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Table 1. Description of enzymatically produced and purified AXOS/XOS  
Sample Treatment Composition (%, w/w) 
DDGS-Xyl 
Deproteinised DDGS 
subjected to enzymatic 
hydrolysis with GH11 endo-
xylanase 
Mixture of xylose (47%), 
XOS (DP2-DP6, 36.3%) and 
AXOS (XA3XX, 2.4%) 
DDGS-Xyl+FAE 
Deproteinised DDGS 
subjected to enzymatic 
hydrolysis with GH11 endo-
xylanase and feruloyl 
esterase 
Mixture of xylose (33.5%),  
XOS (DP2-DP6, 46%) and 
AXOS (XA3XX, 5.4%) 
WS-Xyl 
Deproteinised wet solids 
subjected to enzymatic 
hydrolysis with GH11 endo-
xylanase 
Mixture of xylose (30%),  
XOS (DP2-DP6, 41.4%) and 
AXOS (XA3XX, 4.5%) 
WS_Xyl+FAE 
Deproteinised wet solids 
subjected to enzymatic 
hydrolysis with GH11 endo-
xylanase and feruloyl 
esterase 
Mixture of xylose (31%),  
XOS (DP2-DP6, 31.3%) and 
AXOS (XA3XX, 3.1%) 
DDGS AXOS/XOS DP≥3 
Deproteinised DDGS 
subjected to enzymatic 
hydrolysis with GH11 endo-
xylanase and feruloyl 
esterase and fractionated by 
gel filtration 
Mixture of  XOS (DP3-DP6, 
59.3%) and AXOS (XA3XX, 
40.5%) 
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Table 2: 16S rRNA-targeted oligonucleotide probes used in this work.  
 
 
Probe 
name 
Sequence (5’ to 3’) Targeted bacterial group References 
Non Eub ACTCCTACGGGAGGCAGC Negative control (Wallner et al. 
1993) 
Eub338 GCTGCCTCCCGTAGGAGT Total bacteria (Daims et al. 
1999) 
Eub338II GCAGCCACCCGTAGGTGT Total bacteria (Daims et al. 
1999) 
Eub338III GCTGCCACCCGTAGGTGT Total bacteria (Daims et al. 
1999) 
Bif164 CATCCGGCATTACCACCC Bifidobacterium spp. (Langendijk et 
al. 1995) 
Lab158 GGTATTAGCAYCTGTTTCCA Lactobacillus/Enterococcus (Harmsen et al. 
1999) 
Bac303 CCAATGTGGGGGACCTT Bacteroides/Prevotella (Manz et al. 
1996) 
Erec482 GCTTCTTAGTCARGTACCG Eubacterium 
rectale/Clostridium cocoides 
(Clostridium cluster IVXa 
and IVXb) 
(Franks et al. 
1998) 
Rrec584 TCAGACTTGCCGYACCGC Roseburia spp. (Walker et al. 
2005) 
Ato291 GGTCGGTCTCTCAACCC Atopobium cluster (Harmsen et al. 
2000) 
Prop853 ATTGCGTTAACTCCGGCAC Clostridium Cluster IX (Walker et al. 
2005) 
Fprau655 CGCCTACCTCTGCACTAC Faecalibacterium prausnitzii  (Devereux et 
al. 1992) 
DSV687 TACGGATTTCACTCCT Desulfovibrio spp. (Hold et al. 
2003) 
Chis150 TTATGCGGTATTAATCTYCCTTT Clostridium histolyticum  
(Clostridium cluster I and II) 
(Franks et al. 
1998) 
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Table 3: SCFAs and lactate concentrations (mM) obtained at 0, 8 h and 24 h of fermentation in 
mini-batch cultures. Substrates utilised were: NC (Negative control), FOS (positive control), 
commercial XOS (Longlive Bio-Technology, Shandong, China) and AXOS/XOS fractions DP 
³3. 
 
 
Standard deviation is shown in parentheses (n = 3). 2-way ANOVA with Tukey’s post hoc tests 
were used for the statistical analysis. Significant differences (P < 0.05) among treatment at the 
same time point are indicated with different letters. (*) Significant difference from 0 h 
value, (P < 0.05).
 Acid 
 
 
Time 
 
NC FOS XOS AXOS/XOS DP 
³ 3 
Lactic 0 h 3.99 (2.32)a 3.44 (0.45)a 3.65 (0.20)a 4.09 (0.04)a 
 8 h 12.78 (3.05)a 26.96 (1.16)a 26.58 (12.59)a 12.37 (2.32)a 
  24 h 5.00 (1.96)a 8.77 (7.99)a 10.16 (9.96)a 9.28 (6.16)a 
Formic 0 h 2.75 (1.83)a 2.06 (0.00)a 2.77 (0.64)a 1.77 (0.00)a 
 8 h 2.05 (2.86)a 12.97 (4.45)a* 18.77 (6.41)a 8.08 (4.95)a 
  24 h 2.05 (3.02)a 6.20 (6.72)a* 11.95 (6.55)a 0.65 (2.32)a 
Acetic 0 h 2.35 (1.32)a 5.80 (6.13)a 5.54 (1.00)a 5.60(0.03)a 
 8 h 12.77 (2.95)a 66.51 (4.94)b* 68.89 (4.10)b* 32.03 (13.83)ab 
  24 h 22.67 (2.83)a 69.74 (9.71)b* 72.45 (15.92)b* 59.55(1.94)ab 
Propionic 0 h 9.56 (1.95) 6.42 (3.00) 8.30 (1.50) 8.69 (0.06) 
 8 h 5.02 (3.01)a 9.58 (0.86)a 11.03 (0.68)a 10.59 (0.57)a 
  24 h 7.64 (3.8)a 10.16 (2.54)ab 9.29 (3.05)a 18.80 (1.21)b* 
Butyric 0 h 4.63 (2.12)a 2.88 (3.5)a 0.42 (0.2)a 0.42 (0.1)a 
 
8 h 2.60 (1.75)a 4.77 (2.5)a 4.88 (0.1)a 1.58 (0.1)a 
  24 h 5.00 (3.1)a 13.37 (4.1)b 13.01 (3.5)b 0.68 (0.3)a 
Total SCFAs 0 h 23.27 (5.66)a 20.60 (15.13)a 20.68 (15.13)a 20.87 (0.05)a 
 
8 h 32.99 (17.77)a 120.78 (0.08)bc* 130.14 (4.65)c* 64.12 (21.66)ab 
  24 h 43.48 (12.27)a 108.25 (0.69)b* 116.86 (12.19)b* 92.68 (0.95)b 
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